Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318713 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL10266130 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL15130720 | 0.85 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL15123810 | 0.85 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL29674 | 0.83 | TSHR (0.41) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL20485460 | 0.83 | TSHR (0.41) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL31042234 | 0.83 | TSHR (0.41) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL20485491 | 0.83 | TSHR (0.41) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL20485456 | 0.83 | TSHR (0.41) | CHRM2CHRM1CHRM4CHRM3CYP2D6 | |
| SCHEMBL31042235 | 0.83 | TSHR (0.41) | CHRM2CHRM1CHRM4CHRM3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | CHRM2 4843/4885CHRM1 4819/4885CHRM4 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.